Get The Most Updated RAC-US Dumps To RAC Regulatory Affairs Certification Certification
RAPS Certified RAC-US Dumps Questions Valid RAC-US Materials
NEW QUESTION # 10
The regulatory authority contacts the regulatory affairs professional regarding a complaint about a drug produced by the company. A consumer reported to the regulatory authority that the tablets have a slightly different color and break easily.
Which of the following actions should the regulatory affairs professional take?
- A. Ask that the regulatory authority provide the actual product subject to the complaint.
- B. Respond to the regulatory authority that the product subject to the complaint is most likely a counterfeit product.
- C. Ask that the regulatory authority provide the batch number printed on the packaging of the affected product.
- D. Respond to the regulatory authority that the company will provide copies of the relevant
QC records for batch release.
Answer: C
NEW QUESTION # 11
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Concept development and validation
- B. Product release and validation
- C. Early technical design and product release
- D. Concept development and early technical design
Answer: D
NEW QUESTION # 12
A request was received from a regulatory authority asking the company to conduct product testing in compliance with a newly issued regulation.
What should be done. What action should the company take FIRST?
- A. Send a letter back to the regulatory authority indicating why the regulation does not apply to the product.
- B. Initiate testing immediately to ensure compliance.
- C. Consult with colleagues about the request.
- D. Contact the regulatory authority that issued this request and discuss the requirement.
Answer: D
NEW QUESTION # 13
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the following?
- A. Late and/or incorrect deliverables
- B. Adverse environmental impacts
- C. Inadequate training
- D. Causes of non-conformities
Answer: D
NEW QUESTION # 14
A regulatory affairs professional is asked to review and update regulatory affairs SOPs.
Which aspect of the SOP Is MOST important to consider?
- A. Scope and level of detail
- B. Expiration date
- C. Revision history
- D. Relevance to regulations
Answer: D
NEW QUESTION # 15
Under which of the following circumstances would a regulatory authority require a more detailed premarket submission, a more rigorous audit, and/or the provision of more performance evaluation data than would normally apply to an IVD device of that risk class?
- A. The device is an updated version of a compliant device from the same manufacturer and contains no substantive change.
- B. The manufacturer's experience level with the type of IVD medical device is limited.
- C. The device incorporates well-established technology that is already present in the market.
- D. Internationally recognized standards are available to cover the main aspects of the device and have been used by the manufacturer.
Answer: B
NEW QUESTION # 16
Company X and Company Y both have products for the treatment of rare genetic diseases.
Company X would like to acquire Company Y but does not know enough about Company Y to make an offer.
What is the MOST appropriate approach that Company X should take to acquire more information about Company Y?
- A. Enter into an agreement with Company Y to perform due diligence.
- B. Recruit a professional to gather confidential intelligence on Company Y.
- C. Perform a thorough library search to gather detailed information on Company Y.
- D. Request the needed information from the Board of Directors of Company Y.
Answer: A
NEW QUESTION # 17
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. Detailed CV of all investigators
- B. Randomization scheme and codes
- C. List of lECs or lRBs
- D. Protocol and protocol amendments
Answer: A
NEW QUESTION # 18
Which of the following statements regarding the off-label use of drugs is CORRECT?
- A. Sponsors are allowed to distribute publications about unapproved uses of approved drugs and devices as long as the marketing application is under review by the regulatory authority.
- B. The peer-reviewed literature can ensure high-quality off-label promotion of medications, thereby increasing access to much needed drugs and devices.
- C. The regulatory authority does not restrict physician prescribing for off-label indications or regulate the manufacturer's promotion for such use.
- D. Although the regulatory authority reviews and approves drugs for specific indications, the approval does not limit the use of those drugs in clinical practice.
Answer: D
NEW QUESTION # 19
A regulatory affairs professional has submitted a package for regulatory review.
According to the regulation, the regulatory authority will need to respond within 90 days of submission.
If there is no response after the deadline, what is the BEST approach?
- A. Contact the local political representative and ask for intervention with the regulatory authority to obtain a decision regarding the submission.
- B. Contact the regulatory authority, ask for clarification about the delay, and demand a decision be made regarding the submission.
- C. Contact the regulatory authority, ask for clarification about the delay, and provide answers to any outstanding questions.
- D. Contact the company legal representative in order to begin legal proceedings to enforce the regulatory authority's response time.
Answer: C
NEW QUESTION # 20
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
- A. Introducing a new analytical method
- B. Strengthening a precaution to the product labeling
- C. Deleting a drug substance
- D. Deleting an ingredient of the drug product
Answer: B
NEW QUESTION # 21
According to the ICH guideline on GMP for API, to which of the following is the MOST stringent requirement applied?
- A. Physical processing and packaging
- B. Introduction of the API starting material
- C. Production of Intermediate(s)
- D. Isolation and purification
Answer: A
NEW QUESTION # 22
A superiority advertising claim for a product versus its competitor's product can only be made under which of the following circumstances?
- A. Results of adequate, well-controlled comparative clinical trial show the product is superior.
- B. Results of a three-year, post-market patient survey indicate the product is superior.
- C. Government survey data indicate the product is superior.
- D. In vitro studies show the product to be superior.
Answer: A
NEW QUESTION # 23
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on the part of the PI. What action should the sponsor take?
- A. Terminate the PI and inform the regulatory authorities.
- B. Increase the frequency of monitoring visits.
- C. Inform the institution that granted a medical license to the Pi.
- D. Send a letter of complaint to the Ethics Committee that approved the site.
Answer: A
NEW QUESTION # 24
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Submit the product for review as a pharmaceutical product in Country Y.
- B. Examine decisions made about similar products in Country Y to propose the classification of the product.
- C. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- D. Apply for review of the additional part of the product as a pharmaceutical product in Country
Answer: D
NEW QUESTION # 25
GHTF recommends that the medical device manufacturer define the scope of the clinical evaluation based on which of the following?
- A. Product literature
- B. Risk analysis
- C. Instructions for use
- D. Essential principles
Answer: B
NEW QUESTION # 26
......
To be eligible to take the RAC-US certification exam, candidates must have a minimum of three years of regulatory experience, with at least one year of experience in the United States. They must also have a bachelor's degree or higher from an accredited institution. Once they have met these requirements, candidates can apply to take the exam, which is offered twice a year in multiple locations around the world.
RAC-US Premium PDF & Test Engine Files with 100 Questions & Answers: https://examcollection.bootcamppdf.com/RAC-US-exam-actual-tests.html